URGN - UroGen Pharma Ltd.

QQQ $ 440.06 $ 3.11 (0.71 %)

DIA $ 388.40 $ -0.11 (-0.03 %)

SPY $ 516.34 $ 2.57 (0.5 %)

TLT $ 90.16 $ 0.28 (0.31 %)

GLD $ 215.21 $ 0.15 (0.07 %)

Previous Close

$ 14.3

Open

$ 14.45

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 13.79 - $ 14.67

52 Week Range

$ 8.69 - $ 24.13

Volume

164,415

Average Volume

Market Cap

487.95M

Beta (5Y Monthly)

$ 1.18

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-14-2024	12-31-2023	10-K
2	11-14-2023	09-30-2023	10-Q
3	08-10-2023	06-30-2023	10-Q
4	05-11-2023	03-31-2023	10-Q
5	03-24-2023	12-31-2022	10-K
6	11-10-2022	09-30-2022	10-Q
7	08-11-2022	06-30-2022	10-Q
8	05-10-2022	03-31-2022	10-Q
9	03-21-2022	12-31-2021	10-K
10	11-15-2021	09-30-2021	10-Q
11	08-04-2021	06-30-2021	10-Q
12	05-13-2021	03-31-2021	10-Q
13	03-18-2021	12-31-2020	10-K
14	11-09-2020	09-30-2020	10-Q
15	08-10-2020	06-30-2020	10-Q
16	05-07-2020	03-31-2020	10-Q
17	03-02-2020	12-31-2019	10-K
18	11-12-2019	09-30-2019	10-Q
19	08-09-2019	06-30-2019	10-Q
20	05-09-2019	03-31-2019	10-Q
21	02-28-2019	12-31-2018	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

HC Wainwright & Co. Reiterates Buy on UroG...
05/06/2024 10:18:10

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price...

Reported Saturday, UroGen Announced ATLAS ...
05/06/2024 07:42:33

New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months UroGen Pha...

Reported Sunday, JELMYTO Demonstrates Rema...
05/06/2024 07:16:37

There Were No Differences in RFS Regarding Usage for Chemoablation or Post-Endoscopic Ablation, Tumor Size, Multifocality, or...

HC Wainwright & Co. Reiterates Buy on UroG...
04/18/2024 10:23:32

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price...

UroGen Announces FDA Acceptance Of IND App...
04/15/2024 12:11:55

UroGen plans to initiate a Phase 3 study to explore the safety and efficacy of UGN-103 in 2024Anticipated advantages include a ...

HC Wainwright & Co. Reiterates Buy on UroG...
04/04/2024 10:35:51

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price...

UroGen Pharma Files Patent Infringement Ac...
04/03/2024 12:26:56

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urot...

why-landos-biopharma-shares-are-trading-higher-by-over-170-here-are-other-stocks-moving-in-mondays-mid-day-session

Why Landos Biopharma Shares Are Trading Hi...
03/25/2024 18:44:08

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

HC Wainwright & Co. Reiterates Buy on UroG...
03/18/2024 10:51:33

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price...

Oppenheimer Maintains Outperform on UroGen...
03/15/2024 12:36:56

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from...

UroGen Sees Full Year 2024 Net Product Rev...
03/14/2024 12:09:01

UroGen Pharma Q4 EPS $(0.72) Misses $(0.68...
03/14/2024 12:06:36

UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.72) per share which missed the analyst consensus estimate of $(0.6...

Earnings Scheduled For March 14, 2024
03/14/2024 09:52:13

Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter.

Earnings Outlook For UroGen Pharma
03/13/2024 18:01:08

UroGen Initiates Submission Of A Rolling N...
01/24/2024 13:18:02

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urot...

UroGen Secures Exclusive License From meda...
01/17/2024 13:10:37

RA Capital Management Discloses 9.99% Pass...
12/29/2023 21:45:08

two-months-after-hamas-attacks-gaza-conflict-intensifies-as-ceasefire-efforts-falter

Two Months After Hamas Attacks, Gaza Confl...
12/07/2023 21:42:14

Two months after Hamas attacks, US President Biden, UNSC & King of Jordan call for ceasefire. Israeli stocks rise, US envoy...

Oppenheimer Maintains Outperform on UroGen...
11/15/2023 18:23:57

Oppenheimer analyst Leland Gershell maintains UroGen Pharma (NASDAQ:URGN) with a Outperform and lowers the price target from...

Earnings Scheduled For November 14, 2023
11/14/2023 13:23:43

Companies Reporting Before The Bell • CureVac (NASDAQ:CVAC) is likely to report quarterly loss at $0.24 per share on revenue o...